Abbott Laboratories $ABT Shares Sold by First National Trust Co

First National Trust Co lowered its position in Abbott Laboratories (NYSE:ABT) by 14.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,488 shares of the healthcare product maker’s stock after selling 7,544 shares during the period. First National Trust Co’s holdings in Abbott Laboratories were worth $5,959,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after acquiring an additional 2,977,715 shares in the last quarter. State Street Corp increased its stake in shares of Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after purchasing an additional 689,517 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Abbott Laboratories by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after purchasing an additional 1,390,554 shares during the last quarter. Norges Bank purchased a new position in Abbott Laboratories in the 2nd quarter valued at about $3,026,180,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock worth $2,022,080,000 after buying an additional 821,325 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was acquired at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ABT shares. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Argus decreased their price objective on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Sanford C. Bernstein lowered their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Jefferies Financial Group increased their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Finally, William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $111.11 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company has a market capitalization of $193.21 billion, a PE ratio of 29.87, a price-to-earnings-growth ratio of 1.76 and a beta of 0.75. The firm’s 50-day moving average is $120.52 and its two-hundred day moving average is $126.80. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.